<DOC>
	<DOC>NCT01241695</DOC>
	<brief_summary>The purpose of the study is to determine the safety, acceptability and the efficacy of a 12-week intervention with a diabetes-specific oral nutritional supplement on glycaemic control in type 2 diabetic patients with or at risk of malnutrition</brief_summary>
	<brief_title>Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<criteria>diagnosis of type 2 diabetes according to the WHO diagnostic criteria for more than 6 months: Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT (oral glucose tolerance test); HbA1c between 6.58.5 % (confirmed in the previous 3 months), capable of using oral nutritional supplementation, on stable and controlled antidiabetic regime for at least 1 months, use of metformin and/or sulphonylureas as oral antidiabetic medication, in need of nutritional support because of ≥5% involuntary weight loss in the last 3 months, ≥10% involuntary weight loss in the last 6 months, inadequate nutritional intake causing failure to meet nutritional requirements or at risk of developing malnutrition diabetes type 1, participation in a clinical trial with an investigational product or regular use of diseasespecific oral nutritional supplements within 4 weeks prior to study start patients requiring a fibre free diet, enteral tube feed or parenteral nutrition, concomitant therapy with systemic glucocorticoids, insulins or antidiabetic medication other than metformin and sulphonylureas, known or suspected intolerance or allergy to any component of the investigational product(s), any acute gastrointestinal disease within 2 weeks prior to study entry, gastrectomy, gastroparesis or other gastric emptying abnormalities, acute sever heart failure (NYHA class 4), liver insufficiency / failure (male: ALAT &gt; 150 U/l; female: ALAT &gt; 120 U/l) or renal failure requiring dialysis, cancer cachexia, galactosaemia, fructosaemia, suspicion of drug abuse, abuse of/addiction to alcohol, pregnant or breast feeding women, or fertile women refusing to use contraceptives, patients with untreated major psychiatric disorder, known HIV positive (safety reasons), patient unable to cooperate adequately</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Oral nutritional supplement, diabetes mellitus type 2, glycaemic control</keyword>
	<keyword>Oral nutritional supplement (Food for special medical purposes)</keyword>
</DOC>